Index

A
ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors
Acetaminophen, 416
Acetylation or methylation, 81
ACSs. See Acute coronary syndromes (ACSs)
Action potential duration (APD), 239, 240, 245, 255
action potential, 251
action potential prolongation, 253
APD90, 245
duration, ventricular action, 239–240
ventricular action potential, 240
Activational effects, 72, 79
Acute coronary syndromes (ACSs), 184, 526
fibrinolysis, 525, 526
percutaneous coronary interventions, 526
reperfusion therapies, 526
Addiction, 114
alcohol, 114–116
amphetamine, 114
cannabis derivates, 114
cigarette smoking, 116
cocaine, 114
deficits, 116
developmental alterations, 116
ecstasy, 114
ethanol, 115
methamphetamine, 114
nicotine, 114
opiates, 114
tranquilizer, 114
Addictive benzodiazepine tranquilisers, 152
ADE. See Adverse drug effects (ADE);
Adverse drug events (ADE)
Adenoma
colorectal, 456
Adrenal failure
breastfeeding, 346
dehydroepiandrosterone, 343
fludrocortisone, 343
hydrocortisone, 342
pregnancy, 344
Adverse drug effects (ADE), 270
adverse allergic reactions in anesthesia, 270
amenorrhea and infertility, 274
nausea and vomiting, 271, 273
opioid-induced endocrinopathy, 274
respiratory depression, 274
sluggish feeling, 273
vomiting, 273
Adverse drug events (ADE), 109, 110, 112, 113
depression, 113
doctors, 113
drug, 112
interactions, 110
polytherapy, 110
social function, 113
symptoms, 113
Adverse effects, 212, 214, 219, 222, 226–229
postoperative nausea and vomiting, 276
respiratory depression, 433
Age-and sex-specific differences, 153
Aging, 110
decreased tolerability, 110
modifications, 110
Aldosterone, 227
Aldosterone receptor antagonist
eplerenone, 226, 227, 229
spironolactone, 226–227
Alzheimer’s disease, 7, 14
Analgesics, 194
Androgen receptor (AR), 551
Androgens, 415, 419, 545
3β-Androstandiol, 562
5-Androstenediol, 562

Anesthesia
  atriocurium, 270
  barbiturates, 270
  drug-induced absence of all perceptions, 270
  emergence time, 270
  epidural analgesia, 273
  inhalatory, 270
  intravenous, 270
  neurosteroides, 270
  non-depolarizing neuroblocking agents, 265
  nonsteroidal anti-inflammatory drugs, 274
  opioid receptor agonists, 266
  pain treatments, 266
  propofol, 265
  rocuronium, 269–270
  vecuronium, 270
  wake, 266

Ang II. See Angiotensin II (Ang II)

Angina pectoris, 184

Angiotensin-converting enzyme (ACE) inhibitors, 164, 186–187, 189, 191, 212, 213, 221–224, 226, 228, 229

Angiotensin II (Ang II), 213, 222–226

Angiotensin II receptor blockers (ARBs), 187, 189

Animal models, 23–42, 213–214, 217, 222
  guinea pigs, 351, 352
  rats, 352
  sheep, 351

Anthracyclin, 420

Antibiotics, 195

Anti-cancer drugs, 422

Anticoagulation
  bivalirudin, 527, 531
  factor Xa inhibitor, 531
  fondaparinux, 531
  low-molecular-weight heparin, 527, 531
  thrombin inhibitor, 527
  unfractionated heparin, 527, 531

Anticonvulsants, 292

Antidepressants, 283–290

Antihypertensive agents, 191

Antihypertensive drug therapy, 191

Anti-inflammatory effects, 354–355

Anti-oestrogens, 552

Antiplatelet treatment
  ADP receptor antagonist, 526
  aspirin, 526
  clopidogrel, 526, 527
  prasugrel, 527
  ticagrelor, 527

Antipsychotics, 287

Antivirals
  acyclovir, 505, 507
  adverse reactions, 504, 509
  alpha/ribavirin, 505
  antiretroviral therapies (ART), 504, 506
  HAART, 505
  oseltamivir, 505, 511, 512
  pegylated interferon, 505
  pegylated interferon alpha and ribavirin, 509
  toxicity, 513
  zanamivir, 505, 511

APD. See Action potential duration (APD)

Apoptosis, 52–55, 59–62
  apoptogenic factors, 53
  apoptotic cell death, 53, 57, 60
  apoptotic injury, 61
  apoptotic pathways, 53, 57
  apoptotic response, 59
  driven cardiovascular pathology, 53
  initial apoptotic, 53
  necrotic fate, 53
  pro- and anti-apoptotic proteins, 59
  pro-apoptotic factors, 56, 57

AR. See Androgen receptor (AR)

ARBs. See Angiotensin II receptor blockers (ARBs)

Aromatase inhibitor, 552

Arrhythmias, 238–240, 242, 243, 245–253, 255–256
  Andersen’s syndrome/LQT7, 248
  antiarrhythmic, 238, 239, 251–252
  antiarrhythmic support, 250
  antiarrhythmic therapy, 238, 246
  arousal-induced arrhythmias, 249
  arrhythmic risks, 240
  atrial fibrillation (AF) episodes, 250
  AV nodal reentrant tachyarrhythmia (AVNRT), 250
  Brugada patients, 254
  Brugada phenotype, 254
  Brugada syndrome, 251, 253, 254
  cardiac events, 242, 248
  inherited ventricular tachycardia syndrome, 251
  long QT syndrome (LQTS), 246–248, 253, 254
  LQT1, 248
  LQT1-13, 248
  LQT2, 248, 249
  LQT3, 248
  LQT3, LQT1, 248
  LQT2 mutations, 248
LQT1 or LQT2, 248
LQT3 patients, 248
reentrant arrhythmias, 241
reentry, 250
sudden cardiac death, 241, 251
sudden death, 248
supra-ventricular tachyarrhythmia
(tachycardia), SVT, 249–250
symptomatic long QT syndrome, 248
tachyarrhythmia, 250
torsades de pointes (TdPs), 240–242, 247,
248, 253, 254, 256
torsades de pointes (TdP)
arhythmias, 248
torsades de pointes (TdP) risk, 248
ventricular tachyarrhythmia, 251
Wolff–Parkinson–White (WPW)
syndrome, 250
Asoprisnil, 558
Aspirin, 188, 191, 416, 454
Atherosclerotic disease, 191
AT1 receptor antagonist
candesartan, 224
irbesartan, 217, 224
losartan, 224
valsartan, 224
Atrial fibrillation, 7, 9, 11, 14, 16, 17,
532–535
Atypical antipsychotics, 288
Autoimmune, 76
Autoimmune diseases, 6, 13, 18
Autonomic regulation, 240
autonomic blockade, 240, 242
autonomic control, 249
autonomic excision, 239
autonomic tone, 239, 244
exercise capacity, 239
para-sympathetic tone, 249
sympathetic nerves, 249
Autophagy, 55–62
autophagic cytoprotection, 61
autophagic pathways, 57
autophagic response, 58
autophagic triggering, 57
autophagic vacuoles, 57
autophagosome, 55–56
cytoprotection pathway, 62
macro-autophagy, 55, 56
micro-autophagy, 55, 56
pathway, 56, 57, 59
process, 55
related genes (Atg), 55
Average expenditure, 153

B
Bazedoxifene, 567
Beers criteria, 154
Behavioral teratogenicity, 282
Benzodiazepine antagonists, 161
Benzodiazepines, 157–162, 195, 296
Beta-blockers, 162–163, 189
bisoprolol, 218
metoprolol, 218, 219
propranolol, 218–219
Bevacizumab, 425, 431–433
Bicalutamide, 551, 575
Bleeding, 451, 531, 532
complications, 11, 14
major, 531
minor, 533
severe, 532
Blood pressure, 191, 213, 216–218,
221–226, 228
Breast cancer, 551, 552, 557

C
CAD. See Coronary artery disease (CAD)
Calcium-channel blockers, 189
amlodipine, 219, 221, 229
felodipine, 221
nifedipine, 219
verapamil, 219–221
Cancer
breast, 454
lung, 453, 457
Carboplatin, 419, 425, 427, 428
Cardiac toxicity, 420
Cardiovascular diseases (CVD), 6, 8, 16–18,
24, 138
Cardiovascular events, 191
Cardiovascular risk, 186, 193, 389
Cardiovascular secondary prevention, 184
Cardiovascular system, 152
Catecholamines, 138
Celecoxib, 457
Cell-based therapies, 137
Cell-mediated immune responses
T cells, 502, 503
Cetuximab, 425, 432
CHF. See Chronic heart failure (CHF)
Cholesterol, 396
HDL-C, 389, 390, 395, 397
LDL, 389, 395
VLDL, 397
Chromosome, 547
Chronic heart failure (CHF), 189
Chronic obstructive pulmonary artery disease, 7, 12
Cisplatin, 417, 425, 427, 428, 434
Clinical studies, 111
exclusion, 111
underrepresentation, 111
Clinical trials, 15–16, 18, 129, 179
Phase I, 130, 140
Phase II, 130, 140
Phase III, 130
Phase IV, 130
Clomiphene citrate, 571
Coagulation problems, 178
Cognitive decline, 138
Colon carcinoma, 12
Comedication, 228
Communication skills, 194, 198
Communication styles, 198, 201
Congenital adrenal hyperplasia, 346–351
breastfeeding, 350
fludrocortisone, 348
glucocorticoid therapy, 347–348
pregnancy, 348, 350
Consulting rates, 173
Contraception, 550, 557
Contraceptives, 561
Convergence hypothesis, 152
Coronary artery disease (CAD), 6, 8, 9, 13, 16, 17
Corticosteroids, 138
Cortisol, 420, 421, 428
Coumestrol, 564
COX-1. See Cyclooxygenase (COX)-1
COX-2, 450
CSE inhibitors, 160
Cultured cells, 136–137
CVD. See Cardiovascular diseases (CVD)
Cyclooxygenase (COX)-1, 450
CYP. See Cytochrome P450
mono-oxygenases (CYP)
Cyproterone acetate, 549, 574
Cytochrome P450 mono-oxygenases (CYP), 94, 96, 102, 103
CYP1A2, 94, 96, 98
CYP3A4, 94, 96, 98
CYP2C9, 98
CYP2C19, 98
CYP2D6, 94, 96, 98
CYP2E1, 94, 96
Cytochromes, 215, 218, 220, 227, 228
Cytokines
IL-1β, 448
IL-6, TNF-α and C-reactive protein, 448
TNF-α, 448
Cytostatic drugs, 413, 428, 434, 435

D
Damage
mucosal, 455
DBP. See Diastolic blood pressure (DBP)
DCM. See Dilated cardiomyopathy (DCM)
Declaration of Geneva, 131
Declaration of Helsinki, 131
Defined daily doses (DDDs) volumes, 164
Depression, 194
DGK. See German Cardiac Society (DGK)
DHT. See Dihydrotestosterone (DHT)
Diabetes, 138–140, 188, 316–331
alpha-glucosidase inhibitors, 322
glitzones, 323
incretin, 324–328
insulin, 328–330
metformin, 318–322
sulfonylureas, 323–324
Diabetes mellitus, 7, 13–14, 190–193
Diabetes processes of care, 191
Diarylpropionitril, 563
Diastolic blood pressure (DBP), 186
Diastolic heart failure, 222
Dienogest, 561
Diethylstilbestrol, 561
Digoxin, 212, 215, 228, 229
Dihydropyrimidine dehydrogenase, 426, 428
Dihydrotestosterone (DHT), 568, 574
Dilated cardiomyopathy (DCM), 11
Disability, 445
Disease
Parkinson, 457
Diuretics, 189, 221–222, 226–229
DNA-binding domain, 545
DNA-repair capacity, 413, 426
Docetaxel, 417, 420, 421
Dosage regime, 413
Dose-related ADRs, 178
cytochrome P 450 activity, 179
difference in body weight, 179
renal clearance, 179
smallest volumes of distribution, 178
Doxorubicin, 417, 420, 423, 428
Drospirenone, 554
Drug development, 15–16, 18
Drug expenditure, 195
Drug prescription, 199
Drug-related problems, 177
female gender was an independent
predictor, 177
Drugs, 239, 242, 245–248, 251–252, 254
anticoagulation, 250
dofetilide, 245
drug manufacturing, 246
E4031, 246
hERG blockade, 247
ibutilide, 243
nonprescription anti-inflammatory, 450
QT-prolonging drugs, 247
survival, 461
Drugs “to avoid in the elderly”, 174
women were more likely, 174
Drug therapy, 201
Drug utilization studies, 156
DUTY registry, 191
Dyslipidemia, 187–188, 390

E
E2. See Estradiol (E2)
ECG. See Electrocardiograms (ECG)
Educational level, 173
E2/ER, 36
EGF. See Epidermal growth factor (EGF)
Eicosanoids, 397
Elderly patients, 194
Elderly people, 156
Electrocardiograms (ECG), 238–240
AH interval, 243
baseline QTC intervals, 248
HV interval, 243
JT intervals, 240, 256
QT, 242, 243
QT and JT, 241
QTc, 241
QTc intervals, 240, 242, 243, 247, 248,
254, 255
QTc prolongation, 254
QTc shortening, 243
QTc values, 242
QT dispersion, 240, 241, 247, 256
QT dispersion and T-wave peak to T-wave
end, 241
QT intervals, 239–243, 245, 247, 249, 254
QT or JT intervals, 241
QT prolongation, 246, 248, 253
QT-prolonging drugs, 247
R and T waves, 240
rate-corrected QT intervals, 238, 239, 249
shorter PR/AH intervals
(conduction time), 250
ST elevation, 243
ST-segment elevation, 251
T-wave peak to T-wave end interval,
240, 241, 256
virtual electrograms, 239
wave interval and PQ or PR interval, 243
Emotional learning, 354
Endometriosis, 552, 553, 558
Endometrium, 550, 551, 553
Endothelin, 216–218
Endothelin receptor (ET) antagonist
atrasentan, 218
bosentan, 218
eclazosentan, 218
sitaxsentan, 218
Epidermal growth factor (EGF), 414, 415,
429, 430, 432
Epigenetics, 79–82
ERα. See Oestrogen receptor alpha (ERα)
ERβ. See Oestrogen receptor beta (ERβ)
ERE, 395
ERs. See Estrogen receptors (ERs)
ESC. See European Cardiac Society (ESC)
Estradiol (E2), 502, 504, 506, 510, 511
Estrogen, 214, 217, 219, 222, 223, 227,
414, 416, 426, 430, 431
Estrogen (17β-estadiol; E2), 24, 25, 30–42
significantly decreased infarct size, 35
Estrogen receptors (ERs), 24–25, 34–42,
389, 395
ERα, 25, 26, 31, 34–36, 38
ERβ, 25, 26, 31–36, 38
Estrogens, 399, 400, 448
17β-estadiol, 401
Ethisterone, 554
Ethynylestradiol, 544, 561
European Cardiac Society (ESC), 17
European Clinical Trials Directive
2001/20/EC, 134
European Medicines Agency
EMEA, 133
European Medicines Agency (EMEA), 139
Events
adverse, 462

F
Family responsibilities, 176
Fatty acid oxidation, 390
FCG. See Four core genotypes (FCG)
FDA. See Food and Drug Administration (FDA)
Federal Food, Drug and Cosmetic Act, 129
Female physicians, 201
Females, 109
Fetal bovine serum, 137
Fibrates, 390, 397, 398
fenofibrate, 399
gemfibrozil, 399
Fibrinolytic therapy
streptokinase, 531
5-Fluorouracil, 420, 422, 426–428
Flutamide, 575
 Follicle-stimulating hormone (FSH), 550, 560
Food and Drug Administration (FDA), 132
Foot examinations, 191
Four core genotypes (FCG), 74–79, 83
FSH. See Follicle-stimulating hormone (FSH)
Fulvestrant, 568
Function
cognitive, 454

G
Gemcitabine, 420
Gender, 3–18, 50–52, 59, 108, 129, 447
 associated, 61
 associated disease, 58
 associated pathogenetic differences, 52
 biased specific analyses, 57
 biased studies, 58
 cytology, 50, 51
 cytopathology derived, 51
 dependent, 54, 60
 determinant, 51
 differences, 52, 54, 55, 57, 58, 60, 61, 177
 disparity, 51, 54, 60, 62
 dyad, 199
 environment, 108
 issue, 51
 perspective, 51, 52
 physiological, 108
 related differences, 54
 related mechanisms, 50
 specific information, 52
 tailored therapies, 61
Gender-related differences
aggregation, 524, 525
anticoagulation, 525
coagulation, 524, 525
platelet activation, 524
platelet function, 524
reactivity, 524

Gene expression, 413–416, 428
BCRP1, 353
CYP2B, 353
mSULT2A, 353
NHE, 354
Gene networks, 70
General accounting office, 132
Genistein, 564
German Cardiac Society (DGK), 17
GH. See Growth hormone (GH)
Glucocorticoids, 545
Glucose metabolism, 388, 390, 392
Glucose tolerance, 392
Glutathione S-transferase A (GST A), 416
GnRH agonists. See Gonadotropin-releasing hormone (GnRH) agonists
Gonadectomy, 137
Gonadotropin-releasing hormone (GnRH) agonists, 553
Gpr 30. See G-protein-coupled receptor (Gpr) 30
G-protein-coupled receptor (Gpr) 30, 560
Growth hormone (GH), 414, 415, 419, 428
GST A. See Glutathione S-transferase A (GST A)
Guidelines, 10, 16–18
Gut toxicity, 412

H
HbA1c, 191, 192, 200
Health Canada, 133
Health outcomes research, 141–142
Heart failure, 6–11, 14–16, 139–140, 213–215, 218, 221, 222, 224, 226–229
Heart failure with preserved ejection fraction (HFpEF), 139
Heart rates, 238, 239, 250
 sine cycle length, 239
 sine node function, 239
Heat-shock proteins (hsp), 547
Hemorrhage
 lower gastrointestinal, 451
Hepatic enzymes, 218
Hepatocellular carcinoma, 7, 12
Hepatocyte nuclear factor (HNF) 3beta, 414
Heterochromatizing factors, 71
Hispanic, 419
Histones, 79, 80
HIV. See Human immunodeficiency virus (HIV)
HNF 3beta. See Hepatocyte nuclear factor (HNF) 3beta
Hodgkin lymphoma, 426, 429, 432
Hormone replacement therapy, 215, 221, 400
Hormones, 114
  - estrogens, 114
  - oral contraceptives (OC), 115
  - pregnancy, 115, 116
  - progesterone, 114
HREC, 134
hsp. See Heat-shock proteins (hsp)
Human immunodeficiency virus (HIV), 185
Human umbilical vein endothelial cells, 137
Humoral immune responses, 513
  - antibody, 502, 508, 509, 511
Hydrocodone, 193
Hypercholesterolemia, 398
Hyperlipidemia, 193
Hypertension, 7, 8, 10, 12, 77–78, 139–140, 186, 193, 216–219, 221, 223–228
Hyperthyroidism, 362–365
  - breastfeeding, 365–369
  - iodine, 368
  - lactation, 368
  - lithium, 367–368
  - pregnancy, 365–369
  - radiiodine, 369
  - thionamides, 363–367
  - thyroid surgery, 367, 368
Hypertriglyceridemia, 398
Hypoglycemia, 393
Hypogonadism, 549, 569
Hyponatremia, 178
Hypothalamus, 415
Hypothyroidism
  - L-T4, 369
  - pregnancy, 372–373
  - selenium, 373–374
  - thyroxine (T4), 370
Innate immune responses
  - dendritic cells (DCs), 502, 503
  - macrophages, 502
  - pattern recognition receptors, 502
  - proinflammatory cytokines, 510
  - type I interferon (IFN), 502
Insulin sensitivity, 392, 394
International Code of Medical Ethics, 131
International Conference on Harmonization
  - Guideline E4, 133
  - Guideline E8, 133
  - Guidelines E18, 133
  - Guidelines M4E, 133
  - ICH, 133
Intolerance, 462
Ion-channels, 212, 219, 244, 245, 253–255
  - cardiac delayed rectifier $K^+$ channels, 248
  - cardiac $Na^+$ channel, 248, 251
  - human ether-a-go-go-related gene (HERG), 245, 246, 254
  - $I_{Ca-T}$, 255
  - $I_Kr$ channel, 248
  - $I_Ks$, 255
  - $I_Ks$ and $I_Kr$, 255
  - $I_Kr$ channel, 248
  - $I_Na$ channel, 248
  - inwardly rectifying $K^+$ current ($I_{K1}$), 255
  - ion currents, 255
  - $K^+$ channel, 248
  - KCNIP2, 254
  - KCNJ2, 248
  - Kir2.3, 254
  - Kir6.2, 254
  - $Na^+$ current, 251
  - SCN5A, 251
  - target—the hERG channel, 246
  - transient outward current ($I_{to}$), 255
  - transient outward ($I_{to}$) currents, 251, 254
  - transient outward ($I_{to}$) $K^+$ channel b-subunit
    - KCNIP2, 254
  - transient outward $K^+$ current, 251
  - T-type $Ca^{2+}$ currents ($I_{Ca-T}$), 255
Irinotecan, 417, 427
Irritable bowel syndrome (IBS), 473–491
  - antidepressants, 485–486
  - antidiarrheal agents, 483–484
  - antispasmodic agents, 482–483
  - clinical implications, 489–491
  - gender, 479–480
  - laxatives, 482
  - new drugs, 487–489
  - pathophysiology, 475–477

I
  - IBS. See Irritable bowel syndrome (IBS)
  - Ifosfamide, 428
Impairment
  - renal, 453
  - inappropriate pain relievers, 176
  - inappropriate prescribing, 169–170
  - Influenza, 138
  - Inflammation, 444
  - Inflammatory bowel syndromes, 7, 12, 17
  - Inhibitors
    - selective COX-2, 457
  - Injections, 195
Irritable bowel syndrome (IBS) (cont.)
plant extracts, 486
probiotics, 486–487
prostaglandin derivatives, 483
serotonergic agents, 484–485
sex differences, 475–477
sex hormones, 477–479
treatment, 480–489

K
Kidney failure, 12–13
Kinin
bradykinin, 222
KRAB zinc finger repressor, 416

L
LDL cholesterol. See Low-density lipoprotein (LDL) cholesterol
Leukotrienes, 446
Levonorgestrel, 554
LH. See Luteinizing hormone (LH)
Ligand-binding domain, 545
Lipid-lowering drugs, 191
Lipid-lowering medication, 186–187
Lipid metabolism, 390, 392, 401
lipolysis, 388
β-oxidation, 388
Lipolysis, 397
Lipoproteins, 400
Lonaprisan, 554, 556, 558
Loop diuretic
furosemide, 227
torasemide, 227, 228
Low-density lipoprotein (LDL) cholesterol, 191
Lung cancer, 427–430, 433
Luteinizing hormone (LH), 550, 560
Lymphoma, 431, 432

M
Mammary gland, 552
MDR1A. See Multidrug-resistance gene 1A (MDR1A)
Mechanisms
molecular, 446
Medication addiction, 162
Medication expenses, 153
Medication prescriptions, 153
Medroxyprogesterone acetate, 554
Melanoma
cutaneous, 456
Menopause, 549
Menstrual cycle, 114, 214, 228, 239, 242–243, 245, 246, 250, 253, 254, 413
early follicular phase, 239
follicular phase, 115, 245, 246, 254
late follicular phase, 239, 243, 253
luteal phases, 114, 239, 242, 243, 245, 246, 254
menopause, 243
menstruation, 252
ovulation, 243
ovulatory, 239
puberty, 242, 248, 253
Meperidine, 194
Metabolic disorders, 389
Metabolic enzymes, 419
Metabolism, 212–215, 218–222, 226–229
Metabolites, 455
Methylation, 79
Metoprolol, 164
MH. See Myocardial hypertrophy (MH)
Microalbuminuria, 186
Mifepristone, 553, 554, 556
Mineralocorticoids, 545
Mitochondrial biogenesis, 396
Monoclonal antibodies, 431–434
Mood stabilisers, 291–292
Morphine, 194
Mortality, 165
Multidrug-resistance gene 1A (MDR1A), 416
Multiparous, 137
Multiple sclerosis, 76, 138
Muscle/fat ratio, 413, 420, 434
Myocardial hypertrophy (MH), 25, 27–36
pathological cardiac hypertrophy, 39
physiological, 27, 32–33, 38
Myocardial infarction, 6–8, 10, 13, 15, 17, 157, 184

N
National Institute of Health (NIH), 132
National Institutes of Health Revitalization Act, 132
Nausea, 421, 425, 428, 434
Necrosis, 55
necrotic cells, 56
Neural tube closure, 77
Neuroleptic drugs, 152
NHRs. See Nuclear hormone receptors (NHRs)
Nilutamide, 575
Nimesulide, 459
Non-prescription drugs, 173
Polymorphisms, 213–214, 217, 222, 223, 228, 394
Polypharmacotherapy, 169
Polypharmacy, 170, 171, 177, 229
being female, 171
large number of medications, 170
potentially inappropriate medications (PIMs), 170
problem of evidence-based medicine and medical progress, 171
risk factor, 170
Polyps
colorectal, 456
Postmenopausal women, 399
Postpubescent, 137
Potentially inappropriate medication, 154
PPARalpha, 389, 390, 397, 400, 401
PPARdelta, 389, 390
PPARgamma, 389, 390, 392, 395, 396
pro12Ala polymorphism, 394
pro12Ala variant, 394, 395
PPARs. See Peroxisome proliferator-activated receptors (PPARs)
PPREs, 390
PR antagonists, 553
Preclinical studies, 129, 135–138
Pregnancies, 131, 132, 140, 141, 280, 445
Pregnenolone, 548
Prenylnaringenin, 564
Prescribed packages, 151
Prescribing physicians, 152
Prescription volumes, 151
Preventive therapies, 198
Primary care physicians (PCPs), 186
PRISCUS, 175
PRISCUS list, 156
Proellex®, 557
Progenitor cells, 136–137
Progesterone (P4), 214, 220, 502, 504, 506, 550, 551, 553
Progesterone receptor (PR), 550, 551
Progestins, 545, 549, 550
Proglynon®, 549
Prophylactic folate treatment, 295
Propranolol, 164
Prostaglandins, 397
Prostate cancer, 551, 569–571
Protein expression, 353–354
Psychiatric disorders, 274–275
Psychopharmacological treatment, 280
Psychotropic drugs, 151, 175
Public interest, 197
Pulmonary disease, 138
Pure Food and Drug Act of 1906, 129–130
Q
Quality of life, 461
R
Raloxifene, 566, 567
RAS. See Renin-angiotensin system (RAS)
Reaction
inflammatory, 449
Receptor
angiotensin II type 1 receptor (AT1-R), 214, 217, 222–225
angiotensin II type 2 receptor (AT2-R), 213, 214, 223–225
ETA receptor, 216–218
ETB receptor, 216–218
Redox-system, 416, 427
Regular monitoring, 178
Remission, 445
Renal clearance, 227
Renal insufficiency, 194
Renin, 222–224, 226, 227
Renin-angiotensin system (RAS), 213, 222–226
Renin inhibitor
aliskiren, 226
Response
immune-inflammatory, 463
poor, 461
Retinoid acid receptors (RXRs), 389–391, 395
Rezulin (troglitazone), 139
Rheumatoid arthritis, 444
Risk factor, 174
Rituximab, 425, 431, 432, 434
Rosiglitazone, 139
RXRs. See Retinoid acid receptors (RXRs)
S
Safe medication therapy, 180
SBP. See Systolic blood pressure (SBP)
Secondary data, 150
Secondary prophylaxis, 162
Sedative and antidepressant drugs, 176
Selective oestrogen receptor modulators, 561
Selective PR modulators (SPRMs), 552, 553
Serotonin reuptake inhibitors (SSRIs), 161
Sex and gender, 265–274
Sex bias, 176
Sex chromosome effects, 72
Sex determination, 70–73
Sex-determining factors, 70
primary, 70, 71
secondary, 70
Sex differences, 23–42
Sexes, 3–18, 51, 52, 55, 61, 108, 129
 anatomical, 108
differences, 58
dimorphisms, 54
hormonal, 108
hormones, 54, 55, 57, 58
specific genetic architecture, 54
specific transcriptional regulation, 54
steroid hormone receptors, 54, 55
Sex-gender differences (SGD), 266–268
body composition, 273
clearance, 271
efficacy, 273
emergence, 271
hormonal variability, 266
metabolism, 267
psychosocial factors, 273
sexual hormones, 266
transport proteins, 267
Sex hormones, 93–100, 102, 103, 214–215,
  217, 219, 225, 228, 242, 244, 252, 254
androgens, 93, 96, 100, 242, 255
androgen therapy, 242
17β-estradiol (E2), 246
dihydrotestosterone, 245
E2, 246, 255
estrogens, 94–98, 100–103, 238, 243,
  245, 250, 254, 255
estrone states, 239
female hormones, 242, 243
ovarian hormones, 250
ovarian steroids, 239, 242, 243, 250
progesterone, 94, 95, 102, 238, 243, 245,
  250, 253–255
progesterins, 97, 98, 102, 103
sex hormonal regulation, 256
sex hormone receptor, 244
sex steroid hormone, 242
sex steroids, 238
testosterone, 94–97, 99, 101, 238, 239,
  242, 245, 253–255
Sexome, 70, 82
Sex-specific, 165
Sex-specific considerations, 173
Sex-specific distribution differences, 157
Sex steroid hormones, 243–245, 252,
  254–255, 513
Sexual differentiation, 70–73
Sexual maturity, 137
Sfy, 74, 78
SGD. See Sex-gender differences (SGD)
Signal transducers and activators of transcription 5b (STAT5b), 413, 414
Skeletal muscle, 269
SLE. See Systemic lupus erythematosus (SLE)
Smoking, 186
Social deprivation, 176
Somatostatin, 414
Spermatogenic cycle, 141
SPRMs. See Selective PR modulators (SPRMs)
Sry, 71–74, 77, 78, 83
SSRIs. See Serotonin reuptake inhibitors (SSRIs)
STAT5b. See Signal transducers and activators of transcription 5b (STAT5b)
Statins, 162–163, 398
Statutory health insurance fund, 150
Steroid, 413–415, 419, 420, 427, 428
Stroke, 6, 7, 14, 16, 17, 138, 139, 157
Substitution hypothesis, 152
Symptoms
  gastrointestinal, 451
Systemic lupus erythematosus (SLE), 76
Systolic blood pressure (SBP), 186
T
Tamoxifen, 551, 558, 564, 566–567
Tanaproget, 559
T2DM. See Type 2 diabetes mellitus (T2DM)
Temozolomide, 423, 427
Teratogenicity, 282
Testosterone (T), 214, 217, 227, 502,
  549, 568–571
Testosterone undecanoate, 573
Thalidomide, 132, 133
Therapy problems, 156
Thiazide diuretic
  hydrochlorothiazide (HCTZ), 224
Thiazolidinediones (TZDs), 390, 393, 396
  pioglitazone, 392–394
  rosiglitazone, 392, 393
Thrombocyte aggregation inhibitors, 157
Thromboembolic events
  adverse complications, 524
  clinical outcomes, 524
  morbidity, 524
  mortality, 524
Thyroid hormone, therapy-related
  antidepressive effects, 374–375
  bile acid metabolism, 376
  cardiovascular effects, 376–377
  energy metabolism, 375
  steroid metabolism, 376
TNF-α inhibitors
  adalimumab, 460
TNF-α inhibitors (cont.)
certolizumab pegol, 460
etanercept, 460
golimumab, 460
infliximab, 460
Torsades de pointes (TdPs), 138
Toxicity, 282
Tranquilisers, 161
Transgenic animal model, 213–214
Trials
clinical, 458
Triglycerides, 395, 397
Type 2 diabetes, 139, 184, 190, 193
Type 2 diabetes mellitus (T2DM), 388, 389, 392, 393
Typical antipsychotics, 287–288
Tyrosine kinase inhibitors, 429, 430
TZDs. See Thiazolidinediones (TZDs)

U
Ulcers
duodenal, 458
gastric, 458
gastroduodenal, 458
Ulipristal, 557
Undecanoate testosterone, 571
Underenrollment, 179
Undertreatment, 16
United States Department of Health and Human Services
Code of Federal Regulations, 131
United States Federal Drug Administration, 139
Unspecific complaints, 165
Urine albumin testing, 191
Uterine fibroids, 552, 556
Uterine leiomyoma, 552

V
Vaccines, 509
adverse reactions, 513
HBV vaccine, 505
HSV-2 gD vaccine, 505
recombinant gD-based HSV-2 vaccine, 507
trivalent inactivated vaccines (TIV), 505, 511
Vasoconstriction, 216, 217, 219, 224–225
Vasodilatation, 216, 225
Vinca alkaloids, 417, 420, 426
Vinorelbine, 426
Viral infections, 501, 513
hepatitis, 508, 512
hepatitis B virus (HBV), 501, 505
hepatitis C virus (HCV), 501, 505, 508
herpes simplex virus, 501, 506, 508, 512–513
herpes simplex virus-type 2 (HSV-2), 505, 506
HSV-type 1 (HSV-1), 506
human, 501
human immunodeficiency virus (HIV), 503–506, 512
immunodeficiency, 501
influenza, 501, 505, 510–513
Vitamin D, 545
Vomiting, 425, 428–429, 434, 435
Vulnerability, 180

W
Women, 110, 171, 172
higher risk for polypharmacy, 172
inappropriateness of care, 110
majority of old people, 173
“Women-are-expressive”-hypothesis, 152
World Medical Association (WMA), 131

X
X-chromosome, 213, 223, 225
Xenobiotics, 413, 427
X-inactivation, 70, 73

Z
Z-drugs, 161